Forty-one MS patients from cohort 1, who had available PBMC samples at baseline and after 6 of months of treatment onset, were included for the gene expression study of IFNAR1, the transmembrane and soluble transcripts of IFNAR2, and MxA gene. Here, MX1 is linked to myeloid sarcoma.